Extended Data Fig. 5: Peripheral blood protein analytes and association with response and overall survival.

(a) Volcano plot demonstrating trend in peripheral blood analytes by Olink from cycle 1 day 1 (C1D1) to cycle 3 day 1 (C3D1) demonstrating largest increase in PD-1 (PDCD1). (b) Peripheral blood protein analyte data. Volcano plot for overall survival (OS) based on C1D1 levels of protein analytes showing log rank test (y-axis) and Cox regression hazard ratio (x-axis). Analytes significant for both tests are shown in pink. A lower hazard ratio (left side of the black line) is associated with reduced risk. (c) Peripheral blood protein analyte data. Volcano plot for overall survival (OS) based on C3D1 levels of protein analytes showing log rank test (y-axis) and Cox regression hazard ratio (x-axis). Analytes significant for both tests are shown in pink. A lower hazard ratio (left side of the black line) is associated with reduced risk. (d) Kaplan-Meier curves showing better OS as measured from C3D1 in patients with lower versus higher peripheral blood levels of angiopoietin-2 (ANGPT2). (e) Peripheral blood protein analyte data. Volcano plot for metastasis-free survival (MFS) based on changes in levels of protein analytes from C1D1 to C3D1 showing log rank test (y-axis) and Cox regression hazard ratio (x-axis). Analytes significant for both tests are shown in pink. A lower hazard ratio (left side of the black line) is associated with reduced risk. (f) Kaplan-Meier curves for the proteins in E showing MFS for patients with an increase in PGF, MMP7, or IL6 from C1D1 to C3D1 versus a decrease in levels of these proteins. (g) Peripheral blood protein analyte data. Volcano plot for OS based on changes in levels of protein analytes from C1D1 to C3D1 showing log rank test (y-axis) and Cox regression hazard ratio (x-axis). Analytes significant for both tests are shown in pink. A lower hazard ratio (left side of the black line) is associated with reduced risk. (h) Peripheral blood protein analyte data. Line plots showing individual changes in protein levels from C1D1 to C3D1. N = 64 patients for each analyte for C1D1 to C3D1 comparisons.